Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 12/20 | 0.53 |
| ▸ | CTSK | P43235 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | PREP | P48147 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6284248 | 0.92 | CMA1 (0.61) | CMA1CTSKCTSLCTSBELANE | |
| SCHEMBL8168155 | 0.92 | CMA1 (0.61) | CMA1CTSKCTSLCTSBELANE | |
| SCHEMBL4445986 | 0.92 | CMA1 (0.61) | CMA1CTSKCTSLCTSBELANE | |
| SCHEMBL17378396 | 0.92 | CMA1 (0.61) | CMA1CTSKCTSLCTSBELANE | |
| SCHEMBL2162326 | 0.92 | CMA1 (0.61) | CMA1CTSKCTSLCTSBELANE | |
| SCHEMBL9546595 | 0.84 | CTSK (0.52) | CMA1CTSKCTSLCTSBPREP | |
| SCHEMBL29787416 | 0.83 | CMA1 (0.53) | CMA1CTSKCTSLCTSBELANE | |
| SCHEMBL25054017 | 0.83 | ACE (0.43) | CMA1CTSKCTSLPREPCTSS | |
| SCHEMBL28576870 | 0.83 | ACE (0.43) | CMA1CTSKCTSLPREPCTSS | |
| SCHEMBL28576872 | 0.83 | ACE (0.43) | CMA1CTSKCTSLPREPCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6693072-B2 | Elastase inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-02-17 | — | — | US | disclosed |
| EP-0804465-B1 | NOVEL ELASTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2003-08-06 | — | — | EP | disclosed |
| US-20030096759-A1 | Novel elastase inhibitors | AVENTISUB II INC. | 2003-05-22 | — | — | US | disclosed |
| WO-1995033763-A1 | NOVEL ELASTASE INHIBITORS | HOECHST MARION ROUSSEL, INC. (US) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096759-A1 | Novel elastase inhibitors | ELANE, SERPINB1, MMP8 | CMA1 75/4885CTSK 162/4885CTSL 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.